Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0600142 (hot flushes)
 1,242 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Premenopausal breast cancer patients frequently develop amenorrhea during adjuvant chemotherapy. Despite psychic distress and severe weight loss are possible causes for secondary amenorrhea in cancer patients, it is in this case due to the gonadotoxicity of the cytostatic drugs. Alkylating agents, such as cyclophosphamide, damage ovaries directly, resulting in ovarian fibrosis, atretic follicles and decline in estrogen production. Elevated plasma levels of LH and FSH show adequate reaction of the hypothalamohypophyseal unit. There is no change in the androgen production of stromal cells as well as in the plasma levels of prolactin and adrenal androgen precursors. Ovarian damage goes along with hot flushes, loss of libido and dyspareunia. The onset of amenorrhea is age- and dose-related. Commonly the changes are irreversible. Estrogen replacement therapy promptly removes menopausal symptoms but is contra-indicated regarding the possible hormone-dependence of the tumor. In this case low dose medroxy-progesterone acetate is indicated.
 ...
PMID:[Effects of adjuvant chemotherapy of breast cancer on gonadal function]. 223 81

The aim of this study was to evaluate the sequelae of menopause and how this can be managed in a primary health care setting. Between June 1992 and June 1994, 261 postmenopausal females who attended the menopause clinic at the Kuwait Maternity Hospital were evaluated clinically and with laboratory investigations; mammography, bone density assessment with quantitative computed tomography (QCT) scan and colposcopy were done for some patients. Ninety percent of the patients attended the clinic because of distressing vasomotor symptoms of hot flushes, night sweats and palpitations, and others because of psychological and/or psychiatric problems and secondary amenorrhea and infertility. About 21.5% of the patients were hypertensive, while 13.8% were diabetic. Nonspecific inflammatory bacterial vaginal infection occurred in 18.4% of the patients. High total cholesterol was found in 26%, high LDL in 20% and low HDL in 17% of the patients. Thirty-one percent of females who had bone density measurement had low bone density, while in 7.7%, mammography was abnormal. The authors conclude that the evaluation of patients prior to beginning estrogen therapy, as well as the follow-up, can be done in the primary health care centers.
 ...
PMID:The experience of a menopause clinic in Kuwait: Implication for primary health care. 1737 10

In this report, we describe a case of a solely inhibin B producing fibrothecoma presenting with secondary amenorrhoea and hot flushes. Typical laboratory findings were an elevated LH, elevated inhibin B, low FSH and low estrogen. The World Health Organization classification of amenorrhoea was not applicable since the combination of low estrogen and low FSH suggested a central cause, whereas actually there was an ovarian cause. With staging laparotomy, a bilateral borderline tumour was detected in combination with a fibrothecoma. This report underpins the concept of inhibin B being a selective FSH secretion inhibitor of ovarian origin. Furthermore, a literature review on these topics is included.
 ...
PMID:Solely inhibin B producing ovarian tumour as a cause of secondary amenorrhoea with hot flushes: case report and review of literature. 2225 64

Prolactin-secreting adenoma is rare in elderly women. Patient's clinical picture may be confused with that of menopause, making diagnosis sometimes difficult. We report the case of a 57-year old woman with a 2-year history of secondary amenorrhea without hot flushes associated with galactorrhea in order to highlight the peculiarities of prolactin-secreting microadenomas. Physical examination confirmed the diagnosis of galactorrhoea and biology showed hyperprolactinemia at mIU/L, FSH = 15.1 IU/L and LH = 4,1 IU/L. Pituitary MRI showed left adenoma measuring 8 mm. Patient's evolution under dopaminergic treatment was marked by the recovery, for a transitional period, of mestrual cycles and the occurrence of hot flushes, normalization of prolactin levels and reduction of adenoma size.
 ...
PMID:[Prolactin-secreting microadenoma in menopausal women]. 2890 4